1. Levin M, Ward TN. Horton’s disease: past and present. Curr Pain Headache Rep. 2005;9(4):259-63. https://doi.org/10.1007/s11916-005-0033-4 https://pubmed.ncbi.nlm.nih.gov/16004841 
2. Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis—is it time to reclassify? Rheumatology (Oxford). 2011;50(4):643-5. https://doi.org/10.1093/rheumatology/keq229 https://pubmed.ncbi.nlm.nih.gov/20647295 
3. Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev. 2012;11(6-7):A544-54. https://doi.org/10.1016/j.autrev.2012.01.003 https://pubmed.ncbi.nlm.nih.gov/22285588 
4. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. https://doi.org/10.1002/art.37715 https://pubmed.ncbi.nlm.nih.gov/23045170 
5. Ness T, Bley TA, Schmidt WA, Lamprecht P. The diagnosis and treatment of giant cell arteritis. Dtsch Arztebl Int. 2013;110(21):376-85. https://pubmed.ncbi.nlm.nih.gov/23795218 
6. Nesher G. Giant cell arteritis. In:  Shoenfeld Y, Cervera R, Gershwin ME, eds. Diagnostic Criteria in Autoimmune Diseases. Totowa NJ: Humana Press; 2008. pp. 73-6. https://doi.org/10.1007/978-1-60327-285-8_13 
7.  . The Incidence Rate of Giant Cell Arteritis in Slovenia. 2015[cited 2016 Aug 11]. Available from: http://acrabstracts.org/abstract/the-incidence-rate-of-giant-cell-arteritis-in-slovenia/ 
8. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(17):1653. https://pubmed.ncbi.nlm.nih.gov/25337759 
9. Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. 2016. https://doi.org/10.1093/rheumatology/kew273 
10. Bienvenu B, Ly KH, Lambert M, Agard C, André M, Benhamou Y, et al.; Groupe d’Étude Français des Artérites des gros Vaisseaux, under the Aegis of the Filière des Maladies Auto-Immunes et Auto-Inflammatoires Rares. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016;37(3):154-65. https://doi.org/10.1016/j.revmed.2015.12.015 https://pubmed.ncbi.nlm.nih.gov/26833145 
11. Liozon E, Ly KH, Robert PY. Ocular complications of giant cell arteritis. Rev Med Interne. 2013;34(7):421-30. https://doi.org/10.1016/j.revmed.2013.02.030 https://pubmed.ncbi.nlm.nih.gov/23523078 
12. González-Gay MA, García-Porrúa C, Llorca J, Hajeer AH, Brañas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79(5):283-92. https://doi.org/10.1097/00005792-200009000-00001 https://pubmed.ncbi.nlm.nih.gov/11039076 
13. González-Gay MA, Blanco R, Rodríguez-Valverde V, Martínez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41(8):1497-504. https://doi.org/10.1002/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z https://pubmed.ncbi.nlm.nih.gov/9704651 
14. Salvarani C, Della Bella C, Cimino L, Macchioni P, Formisano D, Bajocchi G, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford). 2009;48(3):250-3. https://doi.org/10.1093/rheumatology/ken465 https://pubmed.ncbi.nlm.nih.gov/19109317 
15. Ninan J, Lester S, Hill C. Giant cell arteritis. Best Pract Res Clin Rheumatol. 2016;30(1):169-88. https://doi.org/10.1016/j.berh.2016.05.001 https://pubmed.ncbi.nlm.nih.gov/27421223 
16. Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum. 1995;38(3):369-73. https://doi.org/10.1002/art.1780380311 https://pubmed.ncbi.nlm.nih.gov/7880191 
17. Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford). 2001;40(11):1238-42. https://doi.org/10.1093/rheumatology/40.11.1238 https://pubmed.ncbi.nlm.nih.gov/11709607 
18. Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005;84(5):269-76. https://doi.org/10.1097/01.md.0000180042.42156.d1 https://pubmed.ncbi.nlm.nih.gov/16148727 
19. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-8. https://doi.org/10.1002/art.1780330810 https://pubmed.ncbi.nlm.nih.gov/2202311 
20. Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014;48-49:73-5. https://doi.org/10.1016/j.jaut.2014.01.017 https://pubmed.ncbi.nlm.nih.gov/24461386 
21. Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, et al. The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess. 2016;20(90):1-238. https://doi.org/10.3310/hta20900 https://pubmed.ncbi.nlm.nih.gov/27925577 
22. Schmidt WA. Role of ultrasound in the understanding and management of vasculitis. Ther Adv Musculoskelet Dis. 2014;6(2):39-47. https://doi.org/10.1177/1759720X13512256 https://pubmed.ncbi.nlm.nih.gov/24688604 
23. Lee YH, Choi SJ, Ji JD, Song GG. Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis : A meta-analysis. Z Rheumatol. 2016;75(9):924-31. https://doi.org/10.1007/s00393-015-1674-2 https://pubmed.ncbi.nlm.nih.gov/26704559 
24. Hocevar A, Rotar Z, Jese R, Semrl SS, Pizem J, Hawlina M, et al. Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal Study. Medicine (Baltimore). 2016;95(14):e3210. https://doi.org/10.1097/MD.0000000000003210 https://pubmed.ncbi.nlm.nih.gov/27057850 
25. Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol. 2013;2013:912562. https://doi.org/10.1155/2013/912562 https://pubmed.ncbi.nlm.nih.gov/23653652 
26. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al.; European Vasculitis Study Group. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318-23. https://doi.org/10.1136/ard.2008.088351 https://pubmed.ncbi.nlm.nih.gov/18413441 
27. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al.; International Network for the Study of Systemic Vasculitides. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309-18. https://doi.org/10.1002/art.10262 https://pubmed.ncbi.nlm.nih.gov/12115238 
28. Leon L, Rodriguez Rodriguez L, Morado I, Rosales Rosado Z, Vadillo C, Freites D, et al. Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice. Clin Exp Rheumatol. 2018;36 Suppl 111(2):121-8. https://pubmed.ncbi.nlm.nih.gov/29303708 
29. Koster MJ, Yeruva K, Crowson CS, Muratore F, Labarca C. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. 2019;46(5):501-8. https://doi.org/10.3899/jrheum.180429 https://pubmed.ncbi.nlm.nih.gov/30647171 
30. Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106-14. https://doi.org/10.7326/0003-4819-134-2-200101160-00010 https://pubmed.ncbi.nlm.nih.gov/11177313 
31. Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. BioMed Res Int. 2013;2013:120638. https://doi.org/10.1155/2013/120638 https://pubmed.ncbi.nlm.nih.gov/24106691 
32. Voelker R. A First for Giant Cell Arteritis. JAMA. 2017;318(1):20. https://pubmed.ncbi.nlm.nih.gov/28672299 
33. FDA. FDA approves first drug to specifically treat giant cell arteritis. 2017[cited 2017 Jul 25]. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm559791.htm 
34. Conway R, O’Neill L, O’Flynn E, Gallagher P, McCarthy GM, Murphy CC, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016;75(8):1578-9. https://doi.org/10.1136/annrheumdis-2016-209351 https://pubmed.ncbi.nlm.nih.gov/27143653 
35. Conway R, O'Neill L, Gallagher P, O'Flynn E, Murphy C, et al. Long Term Efficacy of Ustekinumab for the Treatment of Giant Cell Arteritis. Abstract number 876. 2016 ACR/ARHP Annual Meeting. November 11-16, 2016; Washington, DC. Available from: https://acrabstracts.org/abstract/long-term-efficacy-of-ustekinumab-for-the-treatment-of-giant-cell-arteritis/ 
36. Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford). 2016;55(1):66-70. https://doi.org/10.1093/rheumatology/kev289 https://pubmed.ncbi.nlm.nih.gov/26286743 
37. Carbonella A, Berardi G, Petricca L, Biscetti F, Alivernini S, Bosello SL, et al. Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone. J Am Geriatr Soc. 2016;64(3):672-374. https://doi.org/10.1111/jgs.14004 https://pubmed.ncbi.nlm.nih.gov/27000356 
38. Seelinger B, Sznajd J, Judge A, Robson JC, Craven A, Jayne M, et al. Predictors of Delay in Diagnosis of Giant Cell Arteritis and Antineutrophil Cytoplasm Antibody Associated Vasculitides: Analysis of Data from the Diagnostic & Classification Criteria in Vasculitis Study. Rheumatology. 2015;54(suppp_l):i172-3. 
39. Ezeonyeji AN, Borg FA, Dasgupta B. Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol. 2011;30(2):259-62. https://doi.org/10.1007/s10067-010-1616-y https://pubmed.ncbi.nlm.nih.gov/21086005 
40. Chandran AK, Udayakumar PD, Crowson CS, Warrington KJ, Matteson EL. The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950-2009. Scand J Rheumatol. 2015;44(3):215-8. https://doi.org/10.3109/03009742.2014.982701 https://pubmed.ncbi.nlm.nih.gov/25606666 
41. Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, Prieto-González S, et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum. 2012;64(3):854-65. https://doi.org/10.1002/art.33411 https://pubmed.ncbi.nlm.nih.gov/21989653 
42. Ciccia F, Rizzo A, Maugeri R, Alessandro R, Croci S, Guggino G, et al. Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis. Ann Rheum Dis. 2016;76(1):235-43. https://doi.org/10.1136/annrheumdis-2016–209217 https://pubmed.ncbi.nlm.nih.gov/27098405 
43. Labarca C, Koster MJ, Crowson CS, Makol A, Ytterberg SR, Matteson EL, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford). 2016;55(2):347-56. https://doi.org/10.1093/rheumatology/kev348 https://pubmed.ncbi.nlm.nih.gov/26385368 
44. Muller G, Devilliers H, Besancenot JF, Manckoundia P. Giant cell arteritis (Horton’s disease) in very elderly patients aged 80 years and older: A study of 25 cases. Geriatr Gerontol Int. 2016;16(6):679-85. https://doi.org/10.1111/ggi.12536 https://pubmed.ncbi.nlm.nih.gov/26081629 
45. Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54(3):463-70. https://doi.org/10.1093/rheumatology/keu329 https://pubmed.ncbi.nlm.nih.gov/25193809 
46. Alba MA, Mena-Madrazo JA, Reyes E, Flores-Suárez LF. Giant cell arteritis in Mexican patients. J Clin Rheumatol. 2012;18(1):1-7. https://doi.org/10.1097/RHU.0b013e31823e2e35 https://pubmed.ncbi.nlm.nih.gov/22157266 
47. Alba MA, García-Martínez A, Prieto-González S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93(5):194-201. https://doi.org/10.1097/MD.0000000000000033 https://pubmed.ncbi.nlm.nih.gov/25181312 
48. Singh AG, Kermani TA, Crowson CS, Weyand CM, Matteson EL, Warrington KJ. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015;42(2):309-15. https://doi.org/10.3899/jrheum.140188 https://pubmed.ncbi.nlm.nih.gov/25512481 
49. Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, Perez-Alvarez R, Gonzalez-Juanatey C, Sanchez-Andrade A, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore). 2007;86(2):61-8. https://doi.org/10.1097/md.0b013e31803d1764 https://pubmed.ncbi.nlm.nih.gov/17435586 
50. Gonzalez-Gay MA, Castañeda S, Llorca J. Giant Cell Arteritis: Visual Loss Is Our Major Concern. J Rheumatol. 2016;43(8):1458-61. https://doi.org/10.3899/jrheum.160466 https://pubmed.ncbi.nlm.nih.gov/27481989 
51. Žigon P, Lakota K, Kuret T, Tomšič M, Čučnik S, Sodin-Šemrl S, et al., eds. Acute Phase Proteins and Interleukin-6 are Important in Distinguishing between Giant Cell Arteritis Positive and Negative Patients. In: 10th international congress on autoimmunity. 6 - 10 April 2016; Leipzig, Germany. Available from: https://www.rsc.org/events/detail/18499/10th-international-congress-on-autoimmunity 
52. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121(7):906-15. https://doi.org/10.1161/CIRCULATIONAHA.109.872903 https://pubmed.ncbi.nlm.nih.gov/20142449 
53. Hernández-Rodríguez J, García-Martínez A, Casademont J, Filella X, Esteban MJ, López-Soto A, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum. 2002;47(1):29-35. https://doi.org/10.1002/art1.10161 https://pubmed.ncbi.nlm.nih.gov/11932875 
54. Roblot P, Morel F, Lelievre E, Gascan H, Wijdenes J, Lecron JC. Serum cytokine and cytokine receptor levels in patients with giant cell arteritis during corticotherapy. J Rheumatol. 1996;23(2):408-10. https://pubmed.ncbi.nlm.nih.gov/8882065 
55. Emilie D, Liozon E, Crevon MC, Lavignac C, Portier A, Liozon F, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol. 1994;39(1):17-24. https://doi.org/10.1016/0198-8859(94)90096-5 https://pubmed.ncbi.nlm.nih.gov/8181959 
56. Lecron JC, Roblot P, Chevalier S, Morel F, Alderman E, Gombert J, et al. High circulating leukaemia inhibitory factor (LIF) in patients with giant cell arteritis: independent regulation of LIF and IL-6 under corticosteroid therapy. Clin Exp Immunol. 1993;92(1):23-6. https://doi.org/10.1111/j.1365-2249.1993.tb05942.x https://pubmed.ncbi.nlm.nih.gov/8096803 
57. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36(9):1286-94. https://doi.org/10.1002/art.1780360913 https://pubmed.ncbi.nlm.nih.gov/8216422 
58. van der Geest KS, Abdulahad WH, Rutgers A, Horst G, Bijzet J, Arends S, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxford). 2015;54(8):1397-402. https://doi.org/10.1093/rheumatology/keu526 https://pubmed.ncbi.nlm.nih.gov/25724206 
59. Terrier B, Geri G, Chaara W, Allenbach Y, Rosenzwajg M, Costedoat-Chalumeau N, et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum. 2012;64(6):2001-11. https://doi.org/10.1002/art.34327 https://pubmed.ncbi.nlm.nih.gov/22147555 
60. Ciccia F, Alessandro R, Rizzo A, Principe S, Raiata F, Cavazza A, et al. Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum. 2011;63(7):2097-104. https://doi.org/10.1002/art.30374 https://pubmed.ncbi.nlm.nih.gov/21452292 
61. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121(7):484-91. https://doi.org/10.7326/0003-4819-121-7-199410010-00003 https://pubmed.ncbi.nlm.nih.gov/8067646 
62. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1990;29(6):456-8. https://doi.org/10.1093/rheumatology/29.6.456 https://pubmed.ncbi.nlm.nih.gov/2124160 
63. Beyer C, Axmann R, Sahinbegovic E, Distler JH, Manger B, Schett G, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis. 2011;70(10):1874-5. https://doi.org/10.1136/ard.2010.149351 https://pubmed.ncbi.nlm.nih.gov/21515917 
64. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011;141:w13156. https://doi.org/10.4414/smw.2011.13156 https://pubmed.ncbi.nlm.nih.gov/21515917 
65. Ferfar Y, Mirault T, Desbois AC, Comarmond C, Messas E, Savey L, et al. Biotherapies in large vessel vasculitis. Autoimmun Rev. 2016;15(6):544-51. https://doi.org/10.1016/j.autrev.2016.02.012 https://pubmed.ncbi.nlm.nih.gov/26883459 
66. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921-7. https://doi.org/10.1016/S0140-6736(16)00560-2 https://pubmed.ncbi.nlm.nih.gov/26952547 
67. Adler S, Reichenbach S, Kuchen S, Wermelinger F, Dan D, Seitz M, et al. Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT. Abstract Number 867. In: 2016 ACR/ARHP Annual Meeting. November 11-16, 2016; Washington, DC. Available from: https://acrabstracts.org/abstract/long-term-efficacy-of-ustekinumab-for-the-treatment-of-giant-cell-arteritis/ 
68. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. In: 2016 ACR/ARHP Annual Meeting. November 11-16, 2016; Washington, DC. Available from: https://acrabstracts.org/abstract/long-term-efficacy-of-ustekinumab-for-the-treatment-of-giant-cell-arteritis/ 
69. Régent A, Redeker S, Deroux A, Kieffer P, Ly KH, Dougados M, et al.; French Vasculitis Group, the Groupe Francais pour l’Etude de l’Artérite à Cellules Géantes, and the Club Rhumatismes et Inflammation. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. J Rheumatol. 2016;43(8):1547-52. https://doi.org/10.3899/jrheum.151252 https://pubmed.ncbi.nlm.nih.gov/27182063 
70. Dejaco C. Role of steroid-sparing agents. In: Dasgupta B, Dejaco C, eds. Polymyalgia Rheumatica and Giant Cell Arteritis. Oxford: Oxford University Press; 2016. pp. 89-95. 
71. Ly KH, Stirnemann J, Liozon E, Michel M, Fain O, Fauchais AL. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine. 2014;81(1):76-8. https://doi.org/10.1016/j.jbspin.2013.06.004 https://pubmed.ncbi.nlm.nih.gov/23890680 
72. Dasgupta B. A randomised, double-blinded, placebo controlled study to assess the efficacy and safety of gevokizumab in the treatment of giant cell arteritis. Second International Symposium and Imaging Workshop Giant Cell Arteritis, Polymyalgia Rheumatica and Large Vessel Vasculitis. Rheumatology. 2014;53:i7. https://doi.org/10.1093/rheumatology/keu197 
73. Espígol-Frigolé G, Corbera-Bellalta M, Planas-Rigol E, Lozano E, Segarra M, García-Martínez A, et al. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis. 2013;72(9):1481-7. https://doi.org/10.1136/annrheumdis-2012-201836 https://pubmed.ncbi.nlm.nih.gov/22993227 
74. Ciccia F, Rizzo A, Guggino G, Cavazza A, Alessandro R, Maugeri R, et al. Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. Rheumatology (Oxford). 2015;54(9):1596-604. https://doi.org/10.1093/rheumatology/kev102 https://pubmed.ncbi.nlm.nih.gov/25862016 
75. Chen Q, Yang W, Gupta S, Biswas P, Smith P, Bhagat G, et al. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity. 2008;29(6):899-911. https://doi.org/10.1016/j.immuni.2008.10.011 https://pubmed.ncbi.nlm.nih.gov/19062315 
76. Márquez A, Hernández-Rodríguez J, Cid MC, Solans R, Castañeda S, Fernández-Contreras ME, et al.; Spanish GCA Consortium. Influence of the IL17A locus in giant cell arteritis susceptibility. Ann Rheum Dis. 2014;73(9):1742-5. https://doi.org/10.1136/annrheumdis-2014-205261 https://pubmed.ncbi.nlm.nih.gov/24919468 
77. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763-76. https://doi.org/10.1038/nrd3794 https://pubmed.ncbi.nlm.nih.gov/23023676 
78. Blain H, Abdelmouttaleb I, Belmin J, Blain A, Floquet J, Guéant JL, et al. Arterial wall production of cytokines in giant cell arteritis: results of a pilot study using human temporal artery cultures. J Gerontol A Biol Sci Med Sci. 2002;57(4):M241-5. https://doi.org/10.1093/gerona/57.4.M241 https://pubmed.ncbi.nlm.nih.gov/11909890 
79. Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford). 2004;43(3):294-301. https://doi.org/10.1093/rheumatology/keh058 https://pubmed.ncbi.nlm.nih.gov/14679293 
80. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al.; Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621-30. https://doi.org/10.7326/0003-4819-146-9-200705010-00004 https://pubmed.ncbi.nlm.nih.gov/17470830 
81. Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, López-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67(5):625-30. https://doi.org/10.1136/ard.2007.082115 https://pubmed.ncbi.nlm.nih.gov/18086726 
82. Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puéchal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074-81. https://doi.org/10.1136/annrheumdis-2013-203586 https://pubmed.ncbi.nlm.nih.gov/23897775 
83. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi NA, Monach PA, Carette S, et al. A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol. 2017;69(4):837-45. https://doi.org/10.1002/art.40044 https://pubmed.ncbi.nlm.nih.gov/28133925 
84. Koster MJ, Matteson EL, Warrington KJ. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr Opin Rheumatol. 2016;28(3):211-7. https://doi.org/10.1097/BOR.0000000000000265 https://pubmed.ncbi.nlm.nih.gov/26885650 
85. Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005;64(7):1099-100. https://doi.org/10.1136/ard.2005.036533 https://pubmed.ncbi.nlm.nih.gov/15958774 
86. Mayrbaeurl B, Hinterreiter M, Burgstaller S, Windpessl M, Thaler J. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin Rheumatol. 2007;26(9):1597-8. https://doi.org/10.1007/s10067-007-0684-0 https://pubmed.ncbi.nlm.nih.gov/17619810 
87. Lally L, Pernis A, Narula N, Huang WT, Spiera R. Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis. Rheumatology (Oxford). 2015;54(3):554-8. https://doi.org/10.1093/rheumatology/keu364 https://pubmed.ncbi.nlm.nih.gov/25213129 
88. Piggott K, Deng J, Warrington K, Younge B, Kubo JT, Desai M, et al. Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation. 2011;123(3):309-18. https://doi.org/10.1161/CIRCULATIONAHA.110.936203 https://pubmed.ncbi.nlm.nih.gov/21220737 
89. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9(12):731-40. https://doi.org/10.1038/nrrheum.2013.161 https://pubmed.ncbi.nlm.nih.gov/24189842 
90. Fernández-Fernández FJ. Treg cells in giant cell arteritis: might they be another target for adjuvant treatment? Comment on the article by Samson et al. Arthritis Rheum. 2013;65(1):289. https://doi.org/10.1002/art.37700 https://pubmed.ncbi.nlm.nih.gov/23001860 
91. Zold E, Szodoray P, Nakken B, Barath S, Kappelmayer J, Csathy L, et al. Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. Autoimmun Rev. 2011;10(3):155-62. https://doi.org/10.1016/j.autrev.2010.09.018 https://pubmed.ncbi.nlm.nih.gov/20868777 
92. Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183(9):5458-67. https://doi.org/10.4049/jimmunol.0803217 https://pubmed.ncbi.nlm.nih.gov/19843932 
93. Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64(11):3788-98. https://doi.org/10.1002/art.34647 https://pubmed.ncbi.nlm.nih.gov/22833233 
94. Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med. 2014;20(11):1327-33. https://doi.org/10.1038/nm.3704 https://pubmed.ncbi.nlm.nih.gov/25282359 
95. Martinez-Taboada VM, Blanco R, Fito C, Pacheco MJ, Delgado-Rodriguez M, Rodriguez-Valverde V. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review. Semin Arthritis Rheum. 2001;30(4):257-71. https://doi.org/10.1053/sarh.2001.9734 https://pubmed.ncbi.nlm.nih.gov/11182026 
96. Elling P, Olsson AT, Elling H. Reduced CD8+ T-cell concentration in peripheral blood of patients with carotid artery stenosis: relation to arteritis temporalis. Br J Rheumatol. 1996;35(7):649-51. https://doi.org/10.1093/rheumatology/35.7.649 https://pubmed.ncbi.nlm.nih.gov/8670598 
97. Samson M, Ly KH, Tournier B, Janikashvili N, Trad M, Ciudad M, et al. Involvement and prognosis value of CD8(+) T cells in giant cell arteritis. J Autoimmun. 2016;72:73-83. https://doi.org/10.1016/j.jaut.2016.05.008 https://pubmed.ncbi.nlm.nih.gov/27236507 
98. Nadkarni S, Dalli J, Hollywood J, Mason JC, Dasgupta B, Perretti M. Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression. Circ Res. 2014;114(2):242-8. https://doi.org/10.1161/CIRCRESAHA.114.301374 https://pubmed.ncbi.nlm.nih.gov/24158630 
